STOP-PIV is enrolling patients in a Phase 3 multi-center trial evaluating our investigational drug candidate, DAS181, as a potential treatment option for lower respiratory tract infection (LRTI) due to a sialic-acid dependent respiratory virus such as parainfluenza (PIV) or influenza virus (IFV) in immunocompromised patients.
Data from the Phase 2 study revealed that if a patient meets criteria listed below, he/she may benefit clinically from receiving DAS181:
- are immunocompromised (have received a stem cell transplant, organ transplant, or chemotherapy).
- have a PIV in lower lung infection.
- are currently receiving supplemental oxygen to help with breathing.
For more information about the STOP-PIV Phase 3 trial (DAS181-3-01), please visit the STOP-PIV page at www.ClinicalTrials.gov.